Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives.

ABSTRACT:

Background

Comprehensive genomic profiling (CGP) can identify targets beyond standard of care, potentially revolutionizing personalized cancer management. However, conducting well designed studies in this rapidly evolving field is complex and demands time and investments. Consequently, the total added value of CGP remains uncertain. Clinical benefit and costs often are driving factors in coverage decisions. Recently, five additional factors were identified in the literature that can influence the choice for targeted profiling vs. CGP, specifically: "feasibility", "test journey patient/physician", "wider implications of diagnostic results", "organization of laboratories", and "scientific spillover". The objective of the current study is to examine the role and importance assigned to

SUBMITTER: van Schaik LF 

PROVIDER: S-EPMC11583653 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature